Last year, that number shot up to 25,000 totaling $100 million
Metabolic & Blood Sugar Support Aids in blood sugar regulation, especially beneficial for patients with type 2 diabetes or insulin resistance
Nausea is one of the most common side effects experienced when starting GLP-1 receptor agonist medications for type 2 diabetes or weight management
There is no FDA-approved transdermal GLP-1 receptor agonist
The combined effect is straightforward in practice, even though the biology is sophisticated: people simply eat less, feel satisfied sooner, and experience fewer cravings which over weeks and months adds up to substantial, sustained weight loss
The treatment was safe and well-tolerated, and further trials are planned to confirm these results